Sale!

Del5q MDS Test

Original price was: 1,400 د.إ.Current price is: 1,050 د.إ.

-25%

The Del5q Myelodysplastic Syndrome (MDS) Test is a specialized diagnostic procedure aimed at detecting the deletion of a portion of the long arm (q arm) of chromosome 5. This specific chromosomal abnormality is associated with a subtype of Myelodysplastic Syndromes, a group of bone marrow disorders characterized by the production of insufficient and defective blood cells. Identifying the Del5q abnormality is crucial for the diagnosis, prognosis, and treatment planning of patients with MDS.

Performed at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, the test employs sophisticated technologies to analyze the genetic material of cells obtained from a blood or bone marrow sample. The accuracy and reliability of the results make it a valuable tool for hematologists and oncologists in managing MDS.

The cost of the Del5q MDS Test at DNA Labs UAE is 1050 AED. Considering the complexity of the analysis and the insights it provides into the patient’s condition, the test represents a significant step forward in personalized medicine, enabling targeted therapeutic strategies for individuals with this chromosomal deletion.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Del5q MDS Test

Test Name: Del5q MDS Test

Components: Sodium Heparin Vacutainer (2ml)

Price: 1050.0 AED

Sample Condition: Bone Marrow / Peripheral blood

Report Delivery: 3-4 days

Method: FISH

Test Type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: Del(5q) (MDS) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

Del(5q) refers to a specific genetic abnormality in which a portion of the long arm of chromosome 5 is deleted. This genetic abnormality is commonly associated with a type of bone marrow disorder called myelodysplastic syndrome (MDS). MDS is a group of disorders characterized by abnormal production and maturation of blood cells in the bone marrow.

When the 5q deletion occurs in MDS, it is often referred to as del(5q) MDS. This specific subtype of MDS is characterized by a deletion of genetic material on chromosome 5, leading to a specific set of clinical features and prognostic implications.

Patients with del(5q) MDS typically have a distinct clinical presentation, including macrocytic anemia (enlarged red blood cells), thrombocytosis (elevated platelet count), and a relatively favorable prognosis compared to other subtypes of MDS.

Treatment options for del(5q) MDS may include supportive care measures such as blood transfusions and growth factor medications, as well as targeted therapies specifically designed to address the genetic abnormality. One such targeted therapy is lenalidomide, which has shown efficacy in improving blood counts and reducing the need for transfusions in patients with del(5q) MDS.

Overall, del(5q) MDS is a specific genetic abnormality associated with a subtype of MDS, and its diagnosis and management may require specialized testing and treatment approaches.

Test Name Del5q MDS Test
Components Sodium Heparin Vacutainer (2ml)
Price 1050.0 AED
Sample Condition Bone Marrow \/ Peripheral blood
Report Delivery 3-4 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information Del(5q) (MDS) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

Del(5q) refers to a specific genetic abnormality in which a portion of the long arm of chromosome 5 is deleted. This genetic abnormality is commonly associated with a type of bone marrow disorder called myelodysplastic syndrome (MDS). MDS is a group of disorders characterized by abnormal production and maturation of blood cells in the bone marrow.

When the 5q deletion occurs in MDS, it is often referred to as del(5q) MDS. This specific subtype of MDS is characterized by a deletion of genetic material on chromosome 5, leading to a specific set of clinical features and prognostic implications.

Patients with del(5q) MDS typically have a distinct clinical presentation, including macrocytic anemia (enlarged red blood cells), thrombocytosis (elevated platelet count), and a relatively favorable prognosis compared to other subtypes of MDS.

Treatment options for del(5q) MDS may include supportive care measures such as blood transfusions and growth factor medications, as well as targeted therapies specifically designed to address the genetic abnormality. One such targeted therapy is lenalidomide, which has shown efficacy in improving blood counts and reducing the need for transfusions in patients with del(5q) MDS.

Overall, del(5q) MDS is a specific genetic abnormality associated with a subtype of MDS, and its diagnosis and management may require specialized testing and treatment approaches.